Market Cap 720.22M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 824,551
Avg Vol 1,293,958
Day's Range N/A - N/A
Shares Out 138.24M
Stochastic %K 31%
Beta 1.24
Analysts Strong Sell
Price Target $17.88

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
Abovezero0000
Abovezero0000 Jun. 17 at 1:07 AM
$VIR Very likely that the news will be dropped on a monday, only 2 more mondays left in the month (23rd & 31st). Im betting on the 23rd, I think mary ann said something like ”towards the end of the month” so very unlikey they would drop it on the very last day of the month, but still possible. Keep in mind under normal conditions their market cap is off by $150M-$200M off their current cash/cash equivalents. So when next quarter is announced with a cash pile of $865M the market cap should start to fall to high 600’s to low 700’s if theres no major news. But with mary ann saying that they’re in ”Deep discussions” with potential partners recently, anything can happen. Nobody really knows when that news will pop and the extent of how beneficial it will be for us, I would bet that by mid 2026 or sooner is when they should announce a major partnership with the Hepatits D. Obviously they shouldn't want to release crucial data mid 2027 at the same time that they run out cash…
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 14 at 11:57 AM
$VIR are launching a third phase 1 cancer trial this month, so the trial is going to be announced in the next 10 trading days(mkt is closed June 19). I would expect a positive response for the sp on this news as it gives further endorsement to our cancer therapies & to the pro-xten platform we have licensed from Sanofi.
1 · Reply
sittingonagoldmine
sittingonagoldmine Jun. 13 at 9:42 PM
$VIR How can this guy have so many followers posting information which is not right about VIR? He is not even double checking information here! And who is giving him LIKES for misstated information ? Typically, everyone just posting AI driven info and does not double check.... Very bad attitude and wrong!
0 · Reply
jbrown645
jbrown645 Jun. 13 at 6:45 PM
2 · Reply
Dunnieboy1
Dunnieboy1 Jun. 12 at 7:50 AM
$VIR Brii Bio which has exclusive rights to Vir’s Hepatitis therapies in China was up 13% today, let’s hope it’s connected to our therapies.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 11 at 7:06 AM
$VIR i’ve listened to the CEO’s interview with Goldman Sach’s. Confirmed that the 5525 trial is to begin this month. 7 pre-clinical targets are being assessed for further trials. With regard to ‘Hepatitis Delta’ Marianne said Vir were going to retain exclusive rights in America but were in deep discussions with stakeholders/partners with taking the therapies worldwide, this was a change from what had been said previously in my opinion, previously it was my understanding that Vir would retain exclusive worldwide rights to Hep D worldwide(exc China which Brii Bio have the rights) but were looking for partners just on Hep B, i certainly got the impression that there had been progress on the ’partnering side’ with regard to Delta, Hepatitis B never got mentioned.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 10 at 7:22 PM
$VIR if anyone is interested Marianne De Backer is doing a talk at 22:00 uk & you can listen to the webcast under ’events & presentations’.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 10 at 6:20 AM
$VIR hopefully, we get more data released today from the two phase 1 cancer trials Vir are running, last update was early Jan & a start date date for a third cancer trial namely Vir-5525, which is this quarter. --Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 9 at 10:07 PM
$VIR George Scangos former CEO & director has disposed of 50,000 shares, he still hold another 138,000. Probably more stock options converted then sold, as they say ’nice work if you can get it’.
2 · Reply
trading_momentum
trading_momentum Jun. 9 at 1:47 PM
IMO you will continue to stay hot looking for quality under-the-radar equities because that's where the best value in the market is hidden. $WULF $RKLB $OPXS Bio-Tech wise $MYO and $VIR are both worth mentioning. Deep value with serious potential on both equities.
1 · Reply
Latest News on VIR
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 6 weeks ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript


Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 4 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript


Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 5 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data


Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:12 PM EDT - 8 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript


Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:10 PM EDT - 11 months ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript


Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

May 23, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders


Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

May 22, 2024, 8:00 AM EDT - 1 year ago

Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

SAIC


Abovezero0000
Abovezero0000 Jun. 17 at 1:07 AM
$VIR Very likely that the news will be dropped on a monday, only 2 more mondays left in the month (23rd & 31st). Im betting on the 23rd, I think mary ann said something like ”towards the end of the month” so very unlikey they would drop it on the very last day of the month, but still possible. Keep in mind under normal conditions their market cap is off by $150M-$200M off their current cash/cash equivalents. So when next quarter is announced with a cash pile of $865M the market cap should start to fall to high 600’s to low 700’s if theres no major news. But with mary ann saying that they’re in ”Deep discussions” with potential partners recently, anything can happen. Nobody really knows when that news will pop and the extent of how beneficial it will be for us, I would bet that by mid 2026 or sooner is when they should announce a major partnership with the Hepatits D. Obviously they shouldn't want to release crucial data mid 2027 at the same time that they run out cash…
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 14 at 11:57 AM
$VIR are launching a third phase 1 cancer trial this month, so the trial is going to be announced in the next 10 trading days(mkt is closed June 19). I would expect a positive response for the sp on this news as it gives further endorsement to our cancer therapies & to the pro-xten platform we have licensed from Sanofi.
1 · Reply
sittingonagoldmine
sittingonagoldmine Jun. 13 at 9:42 PM
$VIR How can this guy have so many followers posting information which is not right about VIR? He is not even double checking information here! And who is giving him LIKES for misstated information ? Typically, everyone just posting AI driven info and does not double check.... Very bad attitude and wrong!
0 · Reply
jbrown645
jbrown645 Jun. 13 at 6:45 PM
2 · Reply
Dunnieboy1
Dunnieboy1 Jun. 12 at 7:50 AM
$VIR Brii Bio which has exclusive rights to Vir’s Hepatitis therapies in China was up 13% today, let’s hope it’s connected to our therapies.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 11 at 7:06 AM
$VIR i’ve listened to the CEO’s interview with Goldman Sach’s. Confirmed that the 5525 trial is to begin this month. 7 pre-clinical targets are being assessed for further trials. With regard to ‘Hepatitis Delta’ Marianne said Vir were going to retain exclusive rights in America but were in deep discussions with stakeholders/partners with taking the therapies worldwide, this was a change from what had been said previously in my opinion, previously it was my understanding that Vir would retain exclusive worldwide rights to Hep D worldwide(exc China which Brii Bio have the rights) but were looking for partners just on Hep B, i certainly got the impression that there had been progress on the ’partnering side’ with regard to Delta, Hepatitis B never got mentioned.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 10 at 7:22 PM
$VIR if anyone is interested Marianne De Backer is doing a talk at 22:00 uk & you can listen to the webcast under ’events & presentations’.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 10 at 6:20 AM
$VIR hopefully, we get more data released today from the two phase 1 cancer trials Vir are running, last update was early Jan & a start date date for a third cancer trial namely Vir-5525, which is this quarter. --Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 9 at 10:07 PM
$VIR George Scangos former CEO & director has disposed of 50,000 shares, he still hold another 138,000. Probably more stock options converted then sold, as they say ’nice work if you can get it’.
2 · Reply
trading_momentum
trading_momentum Jun. 9 at 1:47 PM
IMO you will continue to stay hot looking for quality under-the-radar equities because that's where the best value in the market is hidden. $WULF $RKLB $OPXS Bio-Tech wise $MYO and $VIR are both worth mentioning. Deep value with serious potential on both equities.
1 · Reply
Winning_calls
Winning_calls Jun. 9 at 1:38 PM
$VIR 😉😉
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 12:00 PM
$VIR 😉😉
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 3:44 AM
$VIR pick me up @ $5.35
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 8 at 9:26 PM
$VIR we were told that Vir was launching a third cancer trial this quarter ’VIR-5525(EGFR)2, we only have about 15 trading days to go so it could be announced any day. Given that Vir normally release news at conferences then Tuesday the 10th could be the day. We went up 58% on the back of the data released from the first two clinical cancer trials, so the news should be well received. Vir are also expected to update the market with regard to ’dose escalation’ from the first two clinical trials, providing it’s gone well we may enjoy a ’day in the sun’.
0 · Reply
habesha_kingtchalla
habesha_kingtchalla Jun. 8 at 8:32 PM
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 5 at 1:27 PM
$VIR on tip ranks today; Roanna Ruiz’s rating is based on Vir Biotechnology’s potential to achieve significant efficacy and safety improvements with its VIR-5500 program. Despite the competition from JNJ’s pasritamig, which has shown a strong safety profile, Ruiz believes that the market for metastatic castration-resistant prostate cancer (mCRPC) is large enough to accommodate multiple T-Cell Engager (TCE) assets. Vir’s ability to dose escalate for enhanced efficacy while maintaining a favorable safety profile is a key factor in her positive outlook. Moreover, while pasritamig presents a challenge with its convenient dosing schedule and safety, its efficacy appears modest, which could allow VIR-5500 to capture a significant market share if it can demonstrate superior results in upcoming data releases. Ruiz expects that the continued optimization of VIR-5500’s dosing regimen and the potential for improved efficacy will attract investor attention, supporting her Buy rating on the stock.
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 3 at 12:16 PM
$VIR Vir have put a load of announcements out with regard to shares & options for directors, just part of their salary packages, the options are exercisable at $4.94 so one would hope they could maintain the share price above that, the options can be converted from next may for aprox 10yrs should they need time😂
1 · Reply
metalcook
metalcook Jun. 2 at 1:44 PM
$ORIC how does this compare to $JANX and $VIR?
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 2 at 10:51 AM
$VIR another cancer trial is being launched sometime this month Viir-5525(EFGR), given that we had a great initial reaction to the dara from the other two phase 1 cancer trials it may give the sp a much needed boost, although history tells us any sp boost is normally short lived.
1 · Reply
FinJay
FinJay May. 30 at 7:47 PM
$VIR https://youtu.be/WQJDAR2cDsQ
0 · Reply
Pharm_Hand
Pharm_Hand May. 30 at 5:09 PM
$VIR All time low. Is now the time to swing this? Trump has me not knowing if things are upside down or sideways out. All I know is VIR's market cap is $656M and cash on hand is $705.6M with the debt subtracted. SMH
1 · Reply
Dunnieboy1
Dunnieboy1 May. 30 at 1:49 PM
$VIR normal service resumed.
0 · Reply